JP5436779B2 - 遺伝子送達用の生分解性架橋カチオン性マルチブロックコポリマーおよびそれを製造する方法 - Google Patents

遺伝子送達用の生分解性架橋カチオン性マルチブロックコポリマーおよびそれを製造する方法 Download PDF

Info

Publication number
JP5436779B2
JP5436779B2 JP2007540022A JP2007540022A JP5436779B2 JP 5436779 B2 JP5436779 B2 JP 5436779B2 JP 2007540022 A JP2007540022 A JP 2007540022A JP 2007540022 A JP2007540022 A JP 2007540022A JP 5436779 B2 JP5436779 B2 JP 5436779B2
Authority
JP
Japan
Prior art keywords
lpei
biodegradable
crosslinked cationic
block
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007540022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519128A5 (2
JP2008519128A (ja
Inventor
スロボドキン，グレゴリー
メイター，マジェド
フェウェル，ジェイソン
アンウァー，クーアシード
Original Assignee
イージェン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イージェン，インコーポレーテッド filed Critical イージェン，インコーポレーテッド
Publication of JP2008519128A publication Critical patent/JP2008519128A/ja
Publication of JP2008519128A5 publication Critical patent/JP2008519128A5/ja
Application granted granted Critical
Publication of JP5436779B2 publication Critical patent/JP5436779B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2007540022A 2004-11-03 2005-11-03 遺伝子送達用の生分解性架橋カチオン性マルチブロックコポリマーおよびそれを製造する方法 Expired - Fee Related JP5436779B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/981,135 2004-11-03
US10/981,135 US8057821B2 (en) 2004-11-03 2004-11-03 Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
PCT/US2005/039779 WO2006052649A2 (en) 2004-11-03 2005-11-03 Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof

Publications (3)

Publication Number Publication Date
JP2008519128A JP2008519128A (ja) 2008-06-05
JP2008519128A5 JP2008519128A5 (2) 2013-09-05
JP5436779B2 true JP5436779B2 (ja) 2014-03-05

Family

ID=36262249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540022A Expired - Fee Related JP5436779B2 (ja) 2004-11-03 2005-11-03 遺伝子送達用の生分解性架橋カチオン性マルチブロックコポリマーおよびそれを製造する方法

Country Status (7)

Country Link
US (2) US8057821B2 (2)
EP (1) EP1807054A4 (2)
JP (1) JP5436779B2 (2)
KR (1) KR101208192B1 (2)
CN (1) CN101094652B (2)
CA (1) CA2585974C (2)
WO (1) WO2006052649A2 (2)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
HUE056941T2 (hu) 2004-12-22 2022-04-28 Nitto Denko Corp Gyógyszerhordozó és gyógyszerhordozó kit fibrózis gátlására
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
DE102005039154A1 (de) * 2005-08-17 2007-03-01 GÖPFERICH, Achim, Prof. Dr. Bioabbaubare Polymere für den Transport von Nukleinsäuren in Zellen
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
EP2134181A4 (en) * 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
CN101970012A (zh) 2007-09-14 2011-02-09 日东电工株式会社 药物载体
US20090130752A1 (en) * 2007-11-07 2009-05-21 University Of Utah Research Foundation Biodegradable poly(disulfide amine)s for gene delivery
AU2008325122A1 (en) * 2007-11-09 2009-05-14 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
US20090171455A1 (en) * 2007-12-31 2009-07-02 Boston Scientific Scimed, Inc. Biodegradable polymers
JP5514736B2 (ja) * 2008-01-11 2014-06-04 セリナ・セラピユーテイツクス・インコーポレーテツド ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
FR2928373B1 (fr) * 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
WO2009114854A1 (en) * 2008-03-14 2009-09-17 Egen, Inc. Biodegradable cross-linked branched poly (alkylene imines)
CA2721183C (en) * 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
KR101132413B1 (ko) * 2009-05-06 2012-04-03 서울대학교산학협력단 Ｓａｒｓ 백신 나노전달체
WO2010132879A2 (en) 2009-05-15 2010-11-18 The Johns Hopkins University Multicomponent degradable cationic polymers
CN101585921B (zh) * 2009-06-18 2010-12-01 天津大学 温度敏感聚乙烯亚胺-接枝-聚丙烯酸寡乙二醇酯嵌段共聚物及制备方法和应用
CN102575204B (zh) * 2009-10-23 2015-02-25 荷兰联合利华有限公司 染料聚合物
CN101812178B (zh) * 2010-04-20 2012-07-04 武汉大学 还原敏感性聚乙烯亚胺衍生物及其制备方法和应用
KR101802988B1 (ko) * 2010-05-14 2017-12-14 헨켈 아이피 앤드 홀딩 게엠베하 중합체 함유 세정 조성물, 이의 제조 방법 및 용도
RU2013103347A (ru) * 2010-06-25 2014-07-27 Торэй Индастриз, Инк. Водорастворимый полимер и водорастворимый комплекс наночастиц
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
CN102174184B (zh) * 2011-01-14 2012-11-21 中国科学院广州生物医药与健康研究院 一种生物可降解的聚合物及其制备方法以及核酸药物运输载体
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2848740A1 (en) 2011-09-16 2013-03-21 Mingxing Wang Amphiphilic cationic polymers for the delivery of therapeutic agents
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
CA2820236C (en) 2012-06-15 2022-07-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system
US10036009B2 (en) 2012-08-03 2018-07-31 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
EP2907876B1 (en) 2012-10-10 2018-08-15 Sichuan University Reduction stimuli-responsive gene vector system and preparation and use thereof
CN103305549B (zh) * 2013-06-19 2015-04-22 四川大学 具有多重氧化还原刺激响应的纳米粒子基因载体系统及其制备方法和应用
KR101452819B1 (ko) 2012-11-01 2014-10-23 국립암센터 환원제 반응형 이황화물 연결자 함유 고분자-광감각제 결합체 및 이를 포함하는 형광 영상 진단 및 광역학 치료용 조성물
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2017500865A (ja) 2013-12-19 2017-01-12 ノバルティス アーゲー レプチンｍＲＮＡの組成物および製剤
JP6608370B2 (ja) 2014-01-17 2019-11-20 シーダーズ―シナイ メディカル センター 受容体標的化構築物およびその使用
US9850293B2 (en) 2014-04-04 2017-12-26 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
CN104109248B (zh) * 2014-06-20 2017-02-01 南开大学 基于桥式双环糊精主客体诱导聚集构筑的聚集体及其应用
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
CN104356395B (zh) * 2014-11-12 2016-08-17 苏州大学 一种阳离子化丝素蛋白、制备方法及其应用
US10709791B2 (en) 2014-11-12 2020-07-14 University Of Washington Stabilized polymeric carriers for therapeutic agent delivery
CN105012957B (zh) * 2015-07-03 2019-03-22 上海交通大学 一种交联型聚乙烯亚胺作为肿瘤蛋白抗原疫苗载体的用途
US20180256730A1 (en) * 2015-09-16 2018-09-13 University Of Utah Research Foundation A polymeric carrier for delivery of a payload to a cell
DE102017003004A1 (de) 2017-03-23 2018-09-27 Friedrich-Schiller-Universität Jena Kationische Polymere mit D-Fructose-Substituenten
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
CA3079428A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
EP3714045A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
MA51523A (fr) 2018-01-05 2020-11-11 Modernatx Inc Polynucléotides codant pour des anticorps anti-virus du chikungunya
WO2019165583A1 (zh) * 2018-02-27 2019-09-06 苏州大学张家港工业技术研究院 一种可逆自修复环氧树脂及其制备与回收重塑方法
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
US20210148918A1 (en) * 2018-04-17 2021-05-20 Purdue Research Foundation Modifying surface of a live cell and the uses thereof
KR101992236B1 (ko) 2018-05-16 2019-06-24 가톨릭대학교 산학협력단 디셀레노디프로피오네이트의 양 말단에 폴리(입실론-카프로락톤)이 공유결합된 환원분해성 폴리(입실론-카프로락톤) 고분자, 이를 포함하는 항암용 조성물 및 약물 전달용 조성물
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN110859969B (zh) * 2018-08-28 2022-01-11 上海市第十人民医院 聚乙烯亚胺修饰的荧光素钠造影剂及其制备方法和应用
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2020056155A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
JP2022500444A (ja) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド
EP3856233A1 (en) 2018-09-27 2021-08-04 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
EP3953473A1 (en) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法
US20230000990A1 (en) * 2019-12-17 2023-01-05 Universiteit Gent Non-viral vectors comprising polypropyleneimine
EP4158005A1 (en) 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2022104131A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20240226025A1 (en) 2021-03-24 2024-07-11 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
TW202305133A (zh) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna組合物及其使用方法
EP4355882A2 (en) 2021-06-15 2024-04-24 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
US20250221931A1 (en) 2022-03-25 2025-07-10 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
CN114920859B (zh) * 2022-05-11 2023-09-26 宁夏医科大学总医院 5-氟尿嘧啶-1-丁酰基-β-环糊精第二面衍生物及制备方法及其应用
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
WO2024103225A1 (zh) * 2022-11-14 2024-05-23 林桂孜 一种阳离子聚酯及其制备方法和应用
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
EP4704816A1 (en) 2023-05-03 2026-03-11 ModernaTX, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
CN119192568A (zh) * 2024-10-11 2024-12-27 湖北中烟工业有限责任公司 还原敏感型超分子基因载体、其制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS592464B2 (ja) * 1980-04-16 1984-01-18 電気化学工業株式会社 熱可塑性樹脂組成物
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US5733462A (en) * 1996-10-03 1998-03-31 Cytec Technology Corp. Cationic water-soluble polymer precipitation in salt solutions
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
EP1133318B1 (en) * 1998-12-04 2007-03-14 California Institute of Technology Supramolecular complexes containing therapeutic agents
DE19933024C2 (de) * 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Kationische Blockcopolymere
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
US6890556B1 (en) * 2001-02-14 2005-05-10 Northwestern University Controlled surface-associated delivery of genes and oligonucleotides
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
US6521340B2 (en) * 2001-03-15 2003-02-18 Norman B. Rainer Sulfur-containing aliphatic polymer for the selective absorption of dissolved metal species
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
GB0221942D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Drug delivery

Also Published As

Publication number Publication date
CA2585974A1 (en) 2006-05-18
WO2006052649A2 (en) 2006-05-18
EP1807054A2 (en) 2007-07-18
KR20070085500A (ko) 2007-08-27
EP1807054A4 (en) 2008-07-23
KR101208192B1 (ko) 2012-12-04
WO2006052649A3 (en) 2006-09-14
US20060093674A1 (en) 2006-05-04
US8057821B2 (en) 2011-11-15
US8445017B2 (en) 2013-05-21
US20120009145A1 (en) 2012-01-12
CN101094652A (zh) 2007-12-26
JP2008519128A (ja) 2008-06-05
CN101094652B (zh) 2011-05-25
CA2585974C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
JP5436779B2 (ja) 遺伝子送達用の生分解性架橋カチオン性マルチブロックコポリマーおよびそれを製造する方法
US20100004315A1 (en) Biodegradable Cross-Linked Branched Poly(Alkylene Imines)
US6652886B2 (en) Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
CN101970541B (zh) 包含非荷电性亲水性嵌段以及侧链的一部分引入了疏水性基团的阳离子性聚氨基酸嵌段的共聚物、及其使用
CN104093768B (zh) 导入有苯基硼酸基的嵌段共聚物及其使用
US20030147958A1 (en) Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
CN103665384B (zh) 新型阳离子接枝共聚物及多重复合非病毒基因载体制备方法和应用
CN105377302B (zh) 聚合物胶束医药组合物
CN115417889A (zh) 一种l-4-二羟基硼苯丙氨酸-n-羧酸内酸酐单体和聚氨基酸及其制备方法和应用
CN111632153B (zh) 一种化学基因药物共载的靶向纳米递药系统及其制备方法
CN104086721B (zh) mPEG-聚(L-谷氨酸-γ-酰肼)-PDMAPMA三嵌段共聚物及其合成方法和应用
WO2023240505A1 (zh) 一种l-4-二羟基硼苯丙氨酸-n-羧酸内酸酐单体和聚氨基酸及其制备方法和应用
CN107266384B (zh) 基于2-氨基十六烷酸的n-羧基内酸酐单体和聚氨基酸及其制备方法
CN115151278A (zh) 用于核酸疗法的靶向肿瘤的多肽纳米颗粒递送系统
Yi et al. Diol glycidyl ether-bridged cyclens: preparation and their applications in gene delivery
US7183263B2 (en) Linear polyethylenimine-sterol conjugates for gene delivery
Choi et al. Characterization of linear polymer-dendrimer block copolymer/plasmid DNA complexes: formation of core-shell type nanoparticles with DNA and application to gene delivery in vitro
CN112843246B (zh) 含cbx3的l-精氨基氨酸化聚胺类聚合物基因载体的制备方法及其应用
CN121779708A (zh) 一种高分子聚合物及其制备方法和在递送核酸中的应用
WO2024214632A1 (ja) ホスホニウム基を有するカチオン性ポリマーおよびこれを含むポリマー粒子または医薬組成物
CN117586524A (zh) 一种用于体内传递核酸物质用pei聚合物材料的组合物及制备方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081007

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110915

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130722

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131211

R150 Certificate of patent or registration of utility model

Ref document number: 5436779

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees